Dutch health technology company Royal Philips (NYSE:PHG) (AEX:PHIA) on Wednesday introduced IntraSight Plus, an interventional cardiology platform cleared for clinical use in the United States and Europe, combining diagnostic and treatment planning tools into a single system.

The platform integrates multiple functions onto one interface, enabling clinicians to diagnose, plan, guide, and verify coronary procedures while supporting improved decision-making and patient outcomes.

Designed to address inefficiencies in percutaneous coronary interventions, where tools such as angiography, intravascular ultrasound, and physiology are often used separately, IntraSight Plus consolidates these capabilities into a unified workflow. The system is designed to reduce operational complexity in catheterisation labs and deliver up to 47% time savings during procedures.

The platform merges Philips' IntraSight and SyncVision technologies, incorporating IVUS and iFR/FFR physiology, alongside co-registration and real-time device visualisation. This integration enables enhanced procedural precision, streamlined data input and communication, and bedside control within the sterile field.

IntraSight Plus also connects with Philips' Azurion platform and PACS system, supporting broader integration within existing lab environments. The system is FDA 510(k) cleared and CE marked, with commercial availability subject to market release and regulatory requirements.